Patents
Sitemap › A61 - Medical or veterinary science; Hygiene › A61K - Preparations for medical, dental, or toilet purposes › A61K 31 - Medicinal preparations containing organic active ingredients
Patents for A61K 31 - Medicinal preparations containing organic active ingredients (785,912)
11/2010
11/17/2010EP2250887A2 Use of non-antibacterial tetracycline analog CMT-1002 and formulations thereof for the treatment of bacterial exotoxins
11/17/2010EP2250500A1 Methods and kit for early detection of acute coronary syndrome and prediction of adverse cardiac events
11/17/2010EP2250267A1 Cationic sirnas, synthesis and use for interfering rna
11/17/2010EP2250265A1 Compositions comprising notch1 sirna and methods of use thereof
11/17/2010EP2250185A1 Novel lupane derivatives
11/17/2010EP2250183A1 Immunostimulatory sirna molecules
11/17/2010EP2250181A1 Ruthenium compounds and compositions
11/17/2010EP2250180A1 Phosphate derivatives of substituted benzoxazoles
11/17/2010EP2250176A1 Substituted spirocyclic piperidine derivatives as histamine-3 (h3) receptor ligands
11/17/2010EP2250174A2 Macrocyclic serine protease inhibitors
11/17/2010EP2250173A1 Imidazopyrazinol derivatives for the treatment of cancers
11/17/2010EP2250172A1 Pyrrolopyrazine kinase inhibitors
11/17/2010EP2250171A2 Antibacterial fluoroquinolone analogs
11/17/2010EP2250170A1 Azaindole compounds for treatment of central nervous system disorders
11/17/2010EP2250169A1 Pyrido [4, 3-d]pyrimidinone derivatives as kinase inhibitors
11/17/2010EP2250168A2 Angiotensin ii receptor antagonists
11/17/2010EP2250167A1 Arylmethylidene heterocycles as novel analgesics
11/17/2010EP2250166A1 Substituted piperidines as renin inhibitors
11/17/2010EP2250165A1 Triazole oxadiazoles derivatives
11/17/2010EP2250163A1 Hepatitis c virus inhibitors
11/17/2010EP2250161A1 Compounds having crth2 antagonist activity
11/17/2010EP2250160A1 Thiophenes and their use as phosphatidylinositol 3-kinase (pi3k) inhibitors
11/17/2010EP2250157A1 Novel heterocyclic compounds
11/17/2010EP2250156A1 Pyrazinone derivatives as insulin secretion stimulators, methods for obtaining them and use thereof for the treatment of diabetes
11/17/2010EP2250155A1 5h-cyclopenta[d]pyrimidines as akt protein kinase inhibitors
11/17/2010EP2250153A1 Substitued-aryl-(imidazole)-methyl)-phenyl compounds as subtype selective modulators of alpha 2b and/or alpha 2c adrenergic receptors
11/17/2010EP2250152A1 Quinolines as inhibitors of farnesyl pyrophosphate synthase
11/17/2010EP2250150A1 Leukotriene b4 inhibitors
11/17/2010EP2250148A2 Crystalline form of calcium-salts of (3s)-aminomethyl-5-methyl-hexanoic acids and methods of use
11/17/2010EP2249880A1 Superabsorbent composition with metal salicylate for odour control
11/17/2010EP2249871A2 Opthalmic composition
11/17/2010EP2249868A1 Use of s-adenosylmethionine (sam) and superoxide dismutase (sod) for the preparation of medicaments for the treatment of alzheimer's disease
11/17/2010EP2249865A2 Breaking immunological tolerance with a genetically encoded unnatural amino acid
11/17/2010EP2249861A1 Treating neurodegenerative diseases with progranulin (pgrn)
11/17/2010EP2249854A1 Improved treatment and prophylaxis
11/17/2010EP2249848A1 Use of cannabinoids in combination with an anti-psychotic medicament
11/17/2010EP2249845A2 Selective agonist of toll-like receptor 3
11/17/2010EP2249844A1 Active substance combination with gemcitabine for the treatment of epithelial cancer
11/17/2010EP2249843A1 Use of immunogenic compositions for the treatment or prevention of pathogen infections
11/17/2010EP2249842A1 Use of 25-hydroxy-vitamin d3 to affect human muscle physiology
11/17/2010EP2249841A1 Treating hypertension with 25-hydroxyvitamin d3
11/17/2010EP2249840A1 Neuroactive steroid compositions and methods of use therefor
11/17/2010EP2249839A2 Fulvestrant formulations
11/17/2010EP2249838A1 Pharmaceutical solid state forms
11/17/2010EP2249837A1 Methods of treating thromboembolic disorders
11/17/2010EP2249836A1 Fluoroquinolone derivatives for ophthalmic applications
11/17/2010EP2249835A1 Methods using immunomodulatory compounds for modulating level of cd59
11/17/2010EP2249834A1 Selective subtype alpha 2 adrenergic agents and methods for use thereof
11/17/2010EP2249833A1 Prodrugs of cgrp receptor antagonist
11/17/2010EP2249832A1 Method for treating fibrosis and cancer with imidazolium and imidazolinium compounds
11/17/2010EP2249831A2 Methods of using (+)-1,4-dihydro-7-ý(3s,4s)-3-methoxy-4-(methylamino)-1-pyrrolidinyl¨-4-oxo-1-(2-thiazolyl)-1,8-naphthyridine-3-carboxylic acid for treatment of antecedent hematologic disorders
11/17/2010EP2249829A1 Tetrahydropyridoethers for treatment of amd
11/17/2010EP2249828A1 Preparation of sulfamide derivatives
11/17/2010EP2249827A1 Use of picoplatin and cetuximab to treat colorectal cancer
11/17/2010EP2249826A1 Compositions and methods of use of compounds to increase cancer patient survival time
11/17/2010EP2249825A1 Treatment methods and compositions for lung cancer, adenocarcinoma, and other medical conditions
11/17/2010EP2249824A1 Lactylates for the prevention and treatment of infections caused by gram-positive bacteria in animals
11/17/2010EP2249822A1 Pharmaceutical compositions and methods utilizing a d-amino acid and an antioxidant for treating neuropsychiatric disorders
11/17/2010EP2249821A1 Use of amidoxime carboxylic acid esters and n-hydroxyguanidine carboxylic acid esters for producing prodrugs
11/17/2010EP2249820A1 Trpa1 antagonists
11/17/2010EP2249819A1 Phytol as a cholesterol lowering agent
11/17/2010EP2249818A1 Hedgehog pathway antagonists and methods of use
11/17/2010EP2249816A1 Formulation and method for the prevention and treatment of bone metastases or other bone diseases
11/17/2010EP2249812A1 Oral pharmaceutical formulations containing gliclazide
11/17/2010EP2249811A1 Pharmaceutical dosage form
11/17/2010EP2249809A1 Powdered protein compositions and methods of making same
11/17/2010EP2249808A2 Solid pharmaceutical dosage form
11/17/2010EP2249806A2 Resveratrol formulations
11/17/2010EP2249805A1 Liquid antiseptic compositions containing iodine and a sugar and/or sugar alcohol
11/17/2010EP2249804A2 Implantable products comprising nanoparticles
11/17/2010EP2249803A2 Estradiol-containing drug delivery system
11/17/2010EP2249792A2 Oral care product and methods of use and manufacture thereof
11/17/2010EP2249789A2 Compositions and methods for the treatment of xerostomia
11/17/2010EP2249788A1 Oral care product and methods of use and manufacture thereof
11/17/2010EP2249787A1 Oral care product and methods of use and manufacture thereof
11/17/2010EP2249786A1 Oral care product and methods of use and manufacture thereof
11/17/2010EP2249785A1 Arginine salts and their uses for the treatment of illnesses in the oral cavity
11/17/2010EP2249784A1 Oral care product and methods of use and manufacture thereof
11/17/2010EP2249783A2 Oral care product and methods of use thereof
11/17/2010EP2249776A2 Effervescent compositions
11/17/2010EP2249775A1 Topical antimicrobial compositions
11/17/2010EP2249773A2 Moisturizing hand sanitizer
11/17/2010EP2249765A1 Dapsone to treat rosascea
11/17/2010EP2249757A2 Monolithic intravaginal rings comprising progesterone and methods of making and uses thereof
11/17/2010EP2249650A1 Anilinopyridines as inhibitors of fak
11/17/2010EP2249646A1 Dual pharmacophores - pde4-muscarinic antagonistics
11/17/2010EP2249644A2 Picoplatin and amrubicin to treat lung cancer
11/17/2010EP2249643A1 Pharmaceutical compositions of a combination of metformin and a dipeptidyl peptidase-iv inhibitor
11/17/2010EP2249641A1 Novel compositions containing xanthohumol-cyclodextrin complexes
11/17/2010EP2173711B1 Phenoxy-pyrrolidine derivative and its use and compositions
11/17/2010EP2099445B1 P53 activating benzoyl urea and benzoyl thiourea compounds
11/17/2010EP2097411B1 3 -amino-imidazo [1,2 -a]pyridine derivatives having an sglt1 and sglt2 inhibiting action, for treating type 1 and type 2 diabetes
11/17/2010EP2054421B1 Pyrazolopyrimidines, a process for their preparation and their use as medicine
11/17/2010EP2021339B1 Rosiglitazone hydrochloride hemihydrate
11/17/2010EP1996291B1 Use of digitalis-like compounds in the treatment of affective disorders
11/17/2010EP1989186B1 Hydantoin based kinase inhibitors
11/17/2010EP1962817B1 Transdermal delivery of a salt form of meptazinol
11/17/2010EP1959955B1 Method of treating abnormal cell growth
11/17/2010EP1934175B1 Anti-hypercholesterolemic compounds
11/17/2010EP1931680B1 Indol-3-yl-carbonyl-azaspiro derivatives as vasopressin receptor antagonists
1 ... 2002 2003 2004 2005 2006 2007 2008 2009 2010 2011 2012 2013 2014 2015 2016 2017 2018 2019 2020 2021 2022 ... 7860